No other conflicts of interest are declared “
“Diarrhoea re

No other conflicts of interest are declared. “
“Diarrhoea remains one of the leading causes of mortality in infants and young children and results in over 1.34 million deaths in this age group every year [1]. Rotaviruses are responsible for almost 40% of all Enzalutamide chemical structure serious diarrhoeal episodes in infants and young children under 5 years of age requiring a health care

visit and are considered the single leading cause of diarrhoea deaths worldwide. Rotavirus is estimated to cause about 114 million episodes of diarrhoea, 25 million clinic visits, 2.4 million hospital admissions and more than 450,000 deaths per year globally [2], with more than 90% of these deaths occurring in the low income countries of South Asia and Sub-Saharan Africa [2] and [3]. Most African infants (>75%) have their first serious infection before their first birthday [4]. Studies have shown that the first natural rotavirus infection is the most severe and provides some protection against subsequent severe rotavirus gastroenteritis (RVGE) [5], [6] and [7]. Oral live attenuated rotavirus vaccines have been ERK inhibitor developed in an attempt to duplicate the protection induced by natural rotavirus infection by stimulating intestinal IgA antibodies and other forms of local immunity. However, the multitude of clinical trials with

various live attenuated, orally administered rotavirus vaccines has not demonstrated a viable immune correlate of protection

[8] and [9]. Nevertheless, the serum IgA immune response to these vaccines is considered the best “surrogate” marker of protection available, and is evaluated with all rotavirus vaccines. Serum neutralizing antibody (SNA) is also considered important but neither measure has been shown to consistently correlate with clinical efficacy [8] and [9]. Two new live oral rotavirus vaccines have now been developed and shown to be safe and efficacious against severe RVGE why in developed populations and in Latin America [5], [10], [11], [12] and [13]. In all these studies with both rotavirus vaccine candidates, robust IgA immune responses were observed in various populations ranging from 85 to 95% [10], [11], [12] and [13]. In 2005, following a review of available efficacy data from trials in European and Latin American countries and considering the past history of diminished performance of live oral vaccines in protecting the poorest children in developing countries, WHO requested the evaluation of these vaccines in Asia and Africa to generate immunogenicity and efficacy data in these populations [14]. In response to this mandate, the PATH Rotavirus Vaccine Program and Merck & Co. Inc.

The natural history of untreated syphilis includes distinct prima

The natural history of untreated syphilis includes distinct primary and secondary stages of disease typified by a chancre at the site of infection and a disseminated rash, respectively. These lesions spontaneously resolve, followed by a period of asymptomatic latency that lasts for the remainder Apoptosis Compound Library price of their lifetimes in most persons. In the pre-antibiotic era, approximately 30% of untreated infected individuals developed tertiary syphilis 10–50 years after initial infection, with the possibility of life-threatening sequelae [36]. The course of untreated infection has provided insight into the critical pathogenic mechanisms utilized by

T. pallidum to establish and maintain a successful infection. Two key mechanisms that are essential for T. pallidum survival are (1) its high invasive capability and (2) its impressive capacity to evade the immune response and persist for extended periods of time. The highly invasive nature of T. pallidum is most dramatically illustrated by the ability of the pathogen to cross the placental barrier to cause CS and by the fact that at least 40% of patients with

early syphilis have CNS invasion [37]. However, dissemination of infection is also exemplified by the widespread secondary rash, the sometimes symptomatic involvement of liver and kidneys, and ocular involvement. Within hours of infection in experimental animals, the highly motile T. pallidum disseminates widely via

the bloodstream and lymphatics [38] and [39], PLX4032 order and in vitro studies have shown T. pallidum can penetrate intact membranes and endothelial cell monolayers [40] and [41]. Invasion of tissues can result only following attachment of T. pallidum to cells (e.g. endothelial cells that comprise capillary walls). Several proteins that are active in attachment to host cells, via extracellular matrix bridges, include Tp0136 [42], Tp0155, Tp0483 [43] and Tp0751/pallilysin [44], [45], [46], [47] and [48]. The invasive capability of T. pallidum is crucial to the development of the many clinical manifestations of syphilis, and elimination of this capability should be a central target of a syphilis aminophylline vaccine to prevent transmission of infectious syphilis, establishment of CS, and progression of disease within an infected individual. Primary and secondary syphilis lesions are infiltrated primarily by T lymphocytes, followed by macrophages. The vast majority of treponemes are cleared, with lesion resolution, shortly after macrophage infiltration [49], [50], [51] and [52]. Detailed examination of the various steps involved in clearance has revealed there is a Th1-type cellular infiltration in which both CD4+ and CD8+ T lymphocytes produce interferon-gamma (IFN-γ). This cytokine attracts and activates macrophages, which are then able to ingest and kill antibody-opsonized treponemes [49] and [53].

Between 2010 and 2030, there will be 69% increase in number of ad

Between 2010 and 2030, there will be 69% increase in number of adults with diabetes in developing countries and 20% increase in developed countries.3 Various PLX3397 drugs presently available to reduce diabetes associated hyperglycaemia are associated with several side-effects. Hence, in the recent years, there is growing interest in herbal medicine all over the world, as they have little or no side effects. Ethnopharmacological survey indicates that more than 1200 plants are used in traditional medicine for antihyperglycaemic activity.4 India is well known for its herbal wealth. Many medicinal plants belonging to Leguminosae (11 sp.), Lamiaceae (8

sp.), Liliaceae (8 sp.), Cucurbitaceae (7 sp.), Asteraceae (6 sp.), Moraceae (6 sp.), Rosaceae (6 sp.), Euphorbiaceae (5 sp.) and Araliaceae (5 sp.) have been studied for treatment of DM.5 Therefore the search for effective and safer antihyperglycemic agents has become an area of current research all over the world.6 The drug Kali or Shyah-Musali, of Ayurvedic system of medicine is derived from the bitter mucilaginous rhizomes of Curculigo orchioides Gaertn. (Family-Hypoxidaceae). It is one of the important Rasayana drugs of Ayurvedic Materia Medica for vigour and vitality and also reputed for its various medicinal properties. 7 It has tonic, aphrodisiac, demulcent, diuretic properties and used in asthma, impotency, jaundice, skin, urinary and venereal diseases. 8 It is used in many Ayurvedic and Unani compound

formulations as an important ingredient.

9 In Unani system it is used for treating diabetes. 10 The screening for the biological activities of this plant showed hypoglycaemic and anticancer MEK phosphorylation activity in the alcoholic extract of rhizome. 11 Although, acclaimed traditionally as antidiabetic, there are very few reports available on scientific studies regarding the effect of C. orchioides Gaertn. rhizome on blood glucose level. Hence, the present study has been undertaken to carry out phytochemical analysis and to Thalidomide establish the antihyperglycaemic effect of aqueous slurry of C. orchioides Gaertn. rhizome on streptozotocin (STZ) induced diabetic rats. The rhizomes of C. orchioides Gaertn. were collected from Badlapur (Maharashtra, India). The herbarium of C. orchioides Gaertn. plant was prepared and authenticated from Blatter Herbarium, St. Xavier’s College, Mumbai. The rhizomes collected were washed under running tap water and were blotted dry. The rhizomes were then cut into small pieces and kept for drying in oven at temperature 40 ± 2 °C for five days. The dried rhizomes were ground into powder and passed through sieve No. 100 and used for further experimental purpose. The Aqueous Slurry of C. orchioides Gaertn. rhizome powder (ASCO) was prepared in water and used for the dosing purpose (1000 mg powder/kg body weight). Preliminary phytochemical analysis of C. orchioides Gaertn. rhizome using various solvents namely water, methanol, ethanol, benzene and petroleum ether was carried out.

In this study, we co-administered Ad-HIV and MVA-HIV, either as a

In this study, we co-administered Ad-HIV and MVA-HIV, either as a mixture or separately, to mice, and we noticed a suppression of HIV-specific effector CD8 T cell immune responses, by both the tetramer assay and ICS. However, the co-administration increased the proportion of HIV-specific memory CD8 T cells. In vitro experiments indicated that the two replication-deficient viral vectors suppressed the transgene expressions via soluble factor(s) secreted by virus-infected cells. These results show that co-administration of the two viral vaccines results in diverse immune responses, compared to the administration of the vaccine alone or the prime-boost

regimen. selleck chemicals llc Traditional vaccination usually uses the same vaccine for prime-boost vaccination (e.g., polio, BCG, and measles vaccines). A recent study suggests that a single vaccine may not elicit an immune response enough to protect against HIV infection. Therefore, the prime-boost regimen with diverse vaccines has

been explored in animal models and has been found to greatly improve immune response [6] and [26]. In current clinical trials, the Ad and MVA vectors were found to have high immunogenicity. Our group and other researchers found that the Ad prime-MVA boost regimen is one of the best MEK activation immune approaches [6] and [26]. For the convenience of clinical use, we explored HIV-specific immune responses induced by co-administering the two vaccines. Surprisingly, co-vaccination did not increase the antigen-specific immune

responses, but further suppressed the responses, detected by a single epitope or the HIV Env peptide pool (Fig. 1). Further study showed that suppression was also effected by mock viral vectors, including humoral immune response (Fig. 2). One explanation is that numerous effector T cells against viral proteins and the HIV gene have been elicited after co-administration, and the Rolziracetam relative percentage of effector CD8 T cells against limited epitopes has subsequently decreased. MVA, differing from vaccinia virus, does not express TNFα, IFNα/β, and IFNγ cytokine receptor homologs, resulting MVA-induced mature DCs produce cytokines such as IFNα without inhibition from cytokine receptor homologs [27] and [28]. Hodge et al. reported that MVA priming-fowlpox vector boosting at same injection site within 7 days induced higher immune response against fowlpox vector expressing gene than boosting within 30 days or boosting at other injection site, which may result from activation of innate immunity by MVA [29]. One explanation of the difference between our results and theirs is that different boosting timing (simultaneous and 7 days late). It has been known that recombinant virus vector will be exhausted within 2 weeks, most of them within 1 week after in vivo administration [30]. The boosting vector may be less affected by soluble factor(s) secreted by MVA.

HCP communication with adolescents and their parents will be infl

HCP communication with adolescents and their parents will be influential in the uptake of STI vaccines. Their communication will be shaped by country-specific factors such as health care systems, financing, and cultural attitudes as well as unique issues surrounding each STI vaccine (e.g., infection risk, pre-existing this website perceptions, vaccine safety and efficacy). As new STI vaccines are developed and licensed, it is critical that HCPs have the requisite knowledge of vaccine-preventable diseases, including epidemiological patterns, vaccine efficacy and safety, vaccination

recommendations and contraindications, and national programs and policies. In addition, HCPs should be knowledgeable and comfortable with adolescent health and adolescent sexuality and ideally work within an infrastructure that allows sufficient access and

time for visits with adolescents and their parents. see more The process of educating health care teams about adolescent health in general and sexual health specifically must begin now because it will serve as the foundation for implementation of STI vaccination programs worldwide. These steps will foster accurate, targeted communication between the team, adolescents, and their parents, which in turn may prevent the delays in STI vaccine uptake seen previously. Dr. Hofstetter is an investigator and Dr. Rosenthal serves as a consultant on studies funded by the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. The authors alone are responsible for the views expressed in this article and do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. “
“Until CYTH4 recently, efforts to control sexually transmitted diseases (STIs) have focused on treatment. Indeed, antivirals can reduce the painful episodes of recurrent genital herpes, and chlamydia,

gonorrhea, trichomonas and syphilis are curable by inexpensive treatments [1]. However, chlamydia and gonorrhea infections can be undetected before complications such as infertility arise [1]. Poor access to effective interventions hinders STI control in much of the world and antibiotic resistance is developing rapidly. Gonorrhea could soon become untreatable. Based on this observation, the development of STI vaccines could have an important impact on public health [1]. Vaccine development is a long and complex process driven by various forces and involving a large number of partners from various sectors and disciplines. This paper describes the current barriers, as well as the “pulling and pushing” forces to the development of STI vaccines.

6–9 8) for 45 min at 4 °C

and washed four times before sa

6–9.8) for 45 min at 4 °C

and washed four times before samples were applied. Sera were applied in serial two-fold or triple-fold dilutions and a mouse control serum sample positive for A/Sidney/5/97 or A/Beijing/262/95 H1N1 was included on each plate. For detection of SIgA, 100 µl of the lavage was used undiluted in the first well and subsequently serial two-fold diluted. The plates were incubated for 1.5 h at 4 °C, washed 3 times and incubated for 1 h at 4 °C with anti-mouse Ig-HRP conjugates (Southern Biotech). After incubation, the plates were washed 3–4 times and incubated for 30 min with Doxorubicin solubility dmso 100 µl staining solution (1 tablet of OPD (o-Phenylenediamine dihydrochloride) dissolved in 100 ml 0.05 M phosphate-citrate buffer pH 5.0

and 40 µl H2O2). After incubation the reaction was stopped by adding 50 µl 2 M H2SO4 per sample and the absorbance was determined at 492 nm. The IAV-specific IFN-? T-cell and IAV-specific B-cell response in the spleen and local draining cervical lymph nodes (CLN) or inguinal lymph nodes (ILN) after i.n. BLP-SV or i.m. SV vaccination, respectively, was assessed by ELISPOT. For detection of IAV-specific selleck B-cells, cells were directly cultured in high protein binding filter plates (MultiScreen-IP, Millipore) that were pre-coated with Vaxigrip® suspension for injection: strains 2009/2010, Sanofi Pasteur MSD, lot: E7068 at 1 µg per well dissolved in 50 µl of PBS. For detection of IAV-specific IFN-? T-cells, cells were cultured in the presence of HA antigen or IMDM (Gibco, Invitrogen) medium as a control that was supplemented with heat-inactivated 5% FCS (Bodinco,

The Netherlands), 5 × 10-5 M 2-mercaptoethanol, penicillin (100 units/ml) and streptomycin (100 µg/ml) (Gibco, Germany) for 72 h at 37 °C in high protein binding filter plates (MultiScreen-IP, Millipore) that were pre-coated with a rat anti-mouse IFN-? monoclonal antibody (clone AN-18, purchased at BD Biosciences, Pharmingen) at MTMR9 0.1 µg per well dissolved in 50 µl of PBS for 48 h at 37 °C. After incubation, spot forming units of IAV-specific B- and T-cells were detected with goat-anti-mouse IgG-biotin (Sigma) and Avidin-AP (Sigma). Plates were developed with NBT-BCIP (Roche) and analyzed by using the Aelvis spotreader and software. Data are shown as IAV-specific IFN-? T-cell or the IAV-specific B-cell count per 106 cells above background. Single cell suspensions were prepared from spleen and draining lymph nodes and cells were cultured for 72 h in the presence of ConA at 2.5 µg/ml or IMDM (Gibco, Invitrogen) at 37 °C. Analyzing the culture supernatants assessed the amount of cytokine secreted during a 72 h T-cell re-stimulation. Briefly, fluoresceinated microbeads coated with capture antibodies for simultaneous detection of IL-17A (TC11-18H10) and IL-5 (TRFK5) were added to 50 µl of culture supernatant. Cytokines were detected by biotinylated antibodies IL17 (DuoSet ELISA kit, R&D systems Europe Ltd, the U.K.

47 (95% CI 0 20 to 0 73) (Figure 4, see also Figure 5 on the eAdd

47 (95% CI 0.20 to 0.73) (Figure 4, see also Figure 5 on the eAddenda for a detailed forest plot.) The effect of exercise training on the ‘sleep latency’ subscale of the Pittsburgh Sleep Quality Index was examined by pooling data from 239 participants across five trials. Participation in exercise training reduced (ie, improved) sleep latency, with an SMD of

0.58 (95% Cl 0.08 to 1.08) (Figure 6, see also Figure 7 on the eAddenda for a detailed forest plot.) Exercise training also reduced the use of medication to assist sleeping, with an SMD of 0.44 (95% Cl 0.14 to MDV3100 0.74) on the ‘use of sleep medication’ subscale of the Pittsburgh Sleep Quality Index. This was based on pooled data from 196 participants across four trials (Figure 8, see also Figure 9 on the eAddenda for a detailed forest plot.) Exercise training did not cause significant improvement in other domains of the Pittsburgh Sleep Quality Index, including sleep duration, sleep efficiency, sleep disturbance, and daytime functioning Cabozantinib ic50 (see Figures 10 to 13 on the eAddenda.) Objective sleep quality: Only one trial measured sleep quality objectively ( King et al 2008). Polysomnography indicated that the subjects who had participated in exercise training spent a significantly lower percentage of time in Stage 1 sleep (between-group difference 2.3%, 95% Cl 0.7 to 4.0,

effect size = 0.66) and a greater percentage in Stage 2 sleep (between-group difference 3.2%, 95% Cl 0.6 to 5.7, effect size = 0.41) relative to the control subjects. However, the study identified no other significant group differences regarding other polysomnographic parameters,

such as sleep latency and efficiency after participation in the 12-month exercise training program. This meta-analysis provides a comprehensive review of randomised trials examining the effects of an exercise training program on sleep quality in middle-aged and older adults with sleep complaints including insomnia, depression, and poor sleep quality. Pooled analyses of the results indicate that exercise training has a moderate beneficial effect on sleep quality, as indicated most by decreases in the global Pittsburgh Sleep Quality Index score, as well as its subdomains of subjective sleep quality, sleep latency, and sleep medication usage. Other sleep time parameters, including sleep duration, efficiency, and disturbance, were not found to improve significantly. These findings demonstrate that the participants did not sleep for a longer duration after participation in exercise training but they nevertheless perceived better sleep quality. Since poor sleep quality and total sleep time each predict adverse health outcomes in the elderly (Pollack et al 1990, Manabe et al 2000), optimal insomnia treatment should not only aim to improve quantity but also self-reported quality of sleep.

, 1995, Franzek et al , 2008 and Hoek et al , 1998) Similar obse

, 1995, Franzek et al., 2008 and Hoek et al., 1998). Similar observations were reported in offspring of women pregnant during Chinese famine in 1959–1961 as higher incidence of schizophrenia was reported in these offspring (St Clair et al., 2005). Interestingly, a study in Russia of individuals exposed to a famine during the same period as the Dutch Hunger Winter, found no adverse effects on metabolic disease susceptibility (Stanner et al., 1997). In contrast to the Netherlands where the famine was followed by a period of growth and abundance, the standard of living in Russia remained poor throughout

adulthood, suggesting that disorders associated with the prenatal environment may occur when the prenatal and postnatal environment do not match. This concept of a mismatch between the early life and adult phenotype resulting in pathology development has been elegantly described by Nederhoff and Schmidt (Nederhof and S3I-201 concentration Schmidt, 2012). The studies in humans investigating the effects of exposure to stressful events during pregnancy like war, however, are confounded by changes in food availability and variation in the severity of exposure within and between studies. Furthermore, data from a Swedish study indicated that the perceived level of stress may be an important factor

was well. During the Chernobyl disaster, the perceived level of stress predicted the offsprings’ risk of emotional and cognitive disorders better than the actual experience level of radiation (Kolominsky et al., 1999). In order to understand the underlying mechanism of prenatal stress exposure on the offspring’s health, better controlled studies are necessary. selleckchem Better control of environmental factors can be obtained by using animal models over in a laboratory setting. The most common models of prenatal stress either use repeated restraint stress or chronic

variable stressors. However, there are some studies that have specifically targeted social stress using a social defeat paradigm. Exposure to prenatal stress (PNS) has been associated with higher risk of affective disorders in humans (Brown et al., 1995 and Watson et al., 1999). Rodent models support this association, as decreased exploration in an elevated plus maze and increased reactivity to novelty was shown in PNS-exposed rats (Vallee et al., 1997), indicative of increased anxiety-like behavior. Additionally, in behavioral tests designed to assess depression-like phenotypes, prenatally-stressed rats display increased immobility, suggesting increased depression-like behavior (Morley-Fletcher et al., 2003 and Morley-Fletcher et al., 2004). Furthermore, PNS rats showed decreased social interaction (Lee et al., 2007), however, there were no differences in sucrose intake in this study (Lee et al., 2007). These studies suggest that, at least in males, PNS exposure may predispose towards a depression- and anxiety-like phenotype.

n ) administration of mice with c-di-GMP induces recruitment of m

n.) administration of mice with c-di-GMP induces recruitment of monocytes and granulocytes [20] and activates the host immune response [21] and [22]. In one study, the lungs and draining lymph nodes from mice intranasally check details treated either with c-di-GMP

or phosphate buffered saline (PBS) were examined 24 or 48 h after treatment for differences in cell number or composition. Results showed that the draining lymph nodes of c-di-GMP-treated mice had significantly higher total cell numbers as well as higher percentages of CD44low cells and CD86 positive cells. In the lung, however, the picture was less clear with no difference in total numbers of monocytes or neutrophils or pulmonary DCs as determined by flow cytometry [21]. However, there was some indication that c-di-GMP did affect lung parenchymal cells in that the lungs from c-di-GMP-treated mice had a larger proportion of alveolar macrophages which were newly recruited (CD11chiMHCIIlowCD11b+). Also, DCs (CD11chiMHCIIhi), although not significantly increased in number, expressed higher levels of CD40 and CD86 than PBS-treated control mice [21]. Work from our own laboratories has indicated that 24 h after a single i.n. administration of c-di-GMP, there is a significant increase in the number of pulmonary DCs with higher expression

of CD40 and CD80 but not CD86 or MHCII [23]. The treatment also induced a rapid but transient recruitment of neutrophils and other inflammatory and cells into the bronchoalveolar space [23] and increased levels of Galunisertib cost proinflammatory cytokines and chemokines IL-12p40, IL-1β, IL-6, keratinocyte derived chemokine (KC), MCP-1, macrophage inflammatory protein (MIP)-1β, RANTES and tumor necrosis factor (TNF)-α in a dose-dependent manner [22]. A number of recent studies have shown that the innate immune response elicited by c-di-GMP is a potent immunomodulator for the treatment of bacterial infections. In this regard, studies of the effect of c-di-GMP on the course of bacterial infection have clearly shown a striking protective

effect of c-di-GMP administration against a number of serious bacterial infections. Using a mouse model of mastitis, Karaolis and co-workers showed that, despite no direct bactericidal activity, c-di-GMP co-administered with S. aureus directly into the mammary glands significantly decreases bacterial burdens [24]. Previous work by the same group had shown that c-di-GMP inhibits biofilm formation of the same S. aureus strain as well as its adherence to HeLa cells [25]. To rule out the possibility that the c-di-GMP-mediated protection is solely due to its role in the inhibition of biofilm formation, subsequent work showed that pretreatment with c-di-GMP 12 and 6 h before intramammary infection with S. aureus also results in a 1.5 log and a 3.

3) In contrast, however, among children aged less than 10 years,

3). In contrast, however, among children aged less than 10 years, the rates of medically attended shingles were much lower for the publicly available period of 2002–2010 than for either the years when vaccine was only available by private purchase (1999–2001)

or those of the pre-vaccine (1994–1998) period. Table 3 and Table 4 display results from this Poisson model. The effect of co-morbidities is much more pronounced Vorinostat molecular weight in the younger age groups than in the older age groups (Table 3). For males aged <10 years, the relative risk of shingles is 2.6 times higher for those with co-morbidities than for those without; this relative risk declines to 0.93 for the 65+ age group. There is a notably sharp decline in the rate of shingles for both females and males under the age of 10 years (Table 4). The annual percentage change of minus 10% represents an annual decrease in the shingles rate starting learn more in and persisting through the public availability period (2002–2010). Prior to this, all age groups had similar trends with slightly increasing rates,

though females had higher annual percentage changes. A sensitivity analysis that included only first episodes did not change estimated parameters. This paper expands the data available on secular trends in shingles incidence by providing additional data from outside the United States. It thus captures data from a population for whom health care and chickenpox vaccination is universally publicly funded and which differs demographically from that of the United States [14]. Our study is population based and we used data from Alberta’s universal publicly funded healthcare system in our analyses. Thus selection bias due to direct financial

costs for health services does not affect our findings. We also have data for both the pre-vaccine era and for a longer period after public funding of chickenpox vaccine than for other reports from Canada [15]. In prior work, we described the epidemiology of medically attended shingles in Alberta between 1986 and 2002 [9]. As in our prior report, we find a continuing trend of increase in crude medically attended shingles rates that began in the pre-vaccine era. Concerns have been raised that chickenpox nearly vaccination programs might lead to a decrease in the hypothesized ‘immune boosting’ effect of exposure to wild virus [2]. One might thus anticipate that there would be an increase in shingles rates in the age groups representing older unvaccinated cohorts [3]. This pattern while present in the publicly available period was also present prior to vaccine licensure. We do not think that this trend would be explained by an increase in health service utilization over the period because the age-specific rates of health service utilization for both males and females in Alberta have been stable until 2010 when a decline was observed for all age groups of both sexes (Alberta Health, unpublished).